Select date
The Times: Coronavirus May Vanish Too Fast for Vaccine Trial
by Erin Elizabeth, Health Nut News:
One of the scientists behind the Oxford coronavirus vaccine has warned there is only a 50 percent chance of it working because cases in the UK are declining so fast.
The University of Oxford’s Jenner Institute and the Oxford Vaccine Group began developing a COVID-19 vaccine in January using a virus taken from chimpanzees.
With the number of UK coronavirus cases dropping every day, there may not be enough people to test it on, according to the institute’s director Professor Adrian Hill, who noted:
“It’s a race against the virus disappearing, and against time. We said earlier in the year that there was an 80% chance of developing an effective vaccine by September.
“But at the moment, there’s a 50% chance that we get no result at all. We’re in the bizarre position of wanting COVID to stay, at least for a little while.”
RELATED STORY:
On Saturday, 282 people reportedly died of the virus in the UK across hospitals, care homes, and the community.
The figure has fallen dramatically since the peak of Britain’s outbreak when almost 1,000 people were dying every day in hospitals alone.
Trials of the vaccine – officially known as ChAdOx1 nCoV-19 (pronounced Chaddox One) – began with an initial phase of testing on 160 healthy volunteers between the ages of 18 and 55 to see if it could effectively fight off the virus.
RELATED STORY:
The study is set to progress to a second and third phase, which will involve testing up to 10,260 people and expanding the age of participants to include children and the elderly.
But if not enough people can catch the virus, scientists will not have enough evidence to prove it is effective and roll it out for NHS use.
ChAdOx1 nCoV-19 is made from ChAdOx1, a weakened version of the common cold virus (adenovirus), which causes infections in chimpanzees.
The virus has been manipulated so that it cannot harm humans. It also contains part of the coronavirus that would trigger the body’s immune response to COVID-19’s spike proteins which it uses to enter human cells and multiply.
Loading...
